# Sermorelin: Evidence, Mechanism, Dosing & Legal Status

> A clinical monograph on sermorelin — the GHRH(1-29) growth-hormone secretagogue once FDA-approved for diagnosis and pediatric GH deficiency. Real but modest, mostly pre-2000 human trials; the anti-aging marketing outruns the data.

*Published 2026-06-30 · Updated 2026-07-01 · By Marcus Feld, PharmD, BCPS*

The short answer
Sermorelin is one of the few growth-hormone secretagogues with **genuine FDA-approval history and real human controlled-trial evidence** — but the trials are small and mostly pre-2000, so its highest evidence grade is **B**. It demonstrably raises endogenous GH and IGF-1 and improved height velocity in some GH-deficient children, yet the popular anti-aging, fat-loss and performance claims rest on weak, dated or absent evidence. It has no FDA-approved finished product today and is prohibited in sport at all times.[1](https://peptidevox.com/#r1)[8](https://peptidevox.com/#r8)

Sermorelin (sermorelin acetate; "GRF 1-29") is the synthetic, amidated 1-29 amino-acid fragment of growth hormone-releasing hormone (GHRH) — the bioactive core of the 44-residue parent hormone. Rather than supplying growth hormone from outside, it prompts the pituitary to secrete the body's *own* GH in physiologic pulses.[5](https://peptidevox.com/#r5)[6](https://peptidevox.com/#r6) It is heavily marketed as an "anti-aging" peptide; its actual proven uses are narrower and older than that narrative suggests. This monograph separates the two.

*This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. Sermorelin has no FDA-approved finished product on the U.S. market; it is available only via pharmacy compounding and is prohibited in sport. Dosing figures are reported strictly as seen in the published literature and historical labeling for completeness — not as recommendations. Consult a licensed clinician before any health decision.*

## What is sermorelin and how does it work?

Sermorelin (CAS 86168-78-7; molecular formula C₁₄₉H₂₄₆N₄₄O₄₂S; molar mass ~3,358 g/mol) is the synthetic amidated 1-29 fragment of endogenous human GHRH — described as "the shortest fully functional fragment of GHRH," retaining essentially full biological activity of the parent hormone.[6](https://peptidevox.com/#r6)[1](https://peptidevox.com/#r1) Mechanistically it is an agonist at the **growth hormone-releasing hormone receptor (GHRHR)**, a Gs-coupled receptor on anterior-pituitary somatotrophs. Binding raises intracellular cAMP, driving GH gene transcription, synthesis and pulsatile release.[5](https://peptidevox.com/#r5)[6](https://peptidevox.com/#r6)

The defining feature is that it is a **secretagogue** — it amplifies an endogenous physiologic process rather than introducing a foreign hormone. Crucially, the downstream output stays under normal negative feedback: rising GH and IGF-1 trigger hypothalamic somatostatin, which dampens further secretion, so supraphysiologic IGF-1 and tachyphylaxis are largely avoided — a key contrast with exogenous recombinant GH.[5](https://peptidevox.com/#r5)[2](https://peptidevox.com/#r2) Sermorelin has a very short plasma half-life of roughly ten to twenty minutes, owing to rapid proteolysis (notably by dipeptidyl peptidase-IV) and renal clearance, yet once-nightly dosing still raises 24-hour integrated GH and serum IGF-1 over days.[5](https://peptidevox.com/#r5)[3](https://peptidevox.com/#r3) That short half-life is precisely what motivated longer-acting derivatives of this scaffold — CJC-1295 ("modified GRF 1-29") and tesamorelin both descend from it.[13](https://peptidevox.com/#r13)

## What is the evidence by indication?

Sermorelin's evidence is genuinely human but uneven — strongest for diagnosis and pediatric GH deficiency (the basis of its FDA approvals), weakest for the consumer anti-aging narrative. The table summarizes where each claim stands.

  Sermorelin evidence by indication

    IndicationBest evidenceGrade

    Diagnostic provocative GH testSingle 1 µg/kg IV bolus distinguishes GH-sufficient from GH-deficient children; basis of 1990 approvalB (established)
    Idiopathic GH deficiency in children30 µg/kg/day SC improved height velocity over 12 months; gains trailed somatropinB (FDA-approved 1997)
    Older-adult GH–IGF-1 axis & body compositionSmall single-blind RCT (n=19): ↑IGF-1, +~1.26 kg LBM in men; a second trial saw no body-composition changeB trending C/D
    Anti-aging / fat loss / performanceBiomarker surrogates, open-label clinic and marketing data; inconsistent across the two controlled trialsC–D (hyped)

**Diagnosis.** A single intravenous bolus of sermorelin 1 µg/kg rapidly and relatively specifically stimulates GH release, distinguishing GH-sufficient from GH-deficient children, and produced fewer false positives than some other provocative tests — which supported FDA approval of Geref Diagnostic in 1990.[1](https://peptidevox.com/#r1)[16](https://peptidevox.com/#r16) Because it acts directly at the pituitary, a normal response cannot exclude GH deficiency of hypothalamic origin, so additional provocative testing is needed in those patients.[1](https://peptidevox.com/#r1)

**Pediatric GH deficiency.** Subcutaneous sermorelin 30 µg/kg/day at bedtime produced significant increases in height velocity sustained over twelve months, with subset data suggesting maintenance through thirty-six months, inducing catch-up growth in the majority of treated children — best in slow-growing, shorter children with delayed bone and height age.[1](https://peptidevox.com/#r1) The important caveat: head-to-head, sermorelin's gains were smaller than once-daily somatropin 30 µg/kg/day, effects on final adult height were never established, and the indication has been largely supplanted by recombinant GH.[1](https://peptidevox.com/#r1)[16](https://peptidevox.com/#r16)

**Older adults.** In a single-blind, randomized, placebo-controlled trial, 19 men and women aged 55-71 received nightly subcutaneous [Nle27]GHRH(1-29)-NH₂ ~10 µg/kg for sixteen weeks: IGF-1 and IGFBP-3 rose within two weeks, with increased lean body mass (men averaging ~1.26 kg), skin thickness, insulin sensitivity and libido — and no one developed supraphysiologic IGF-1.[2](https://peptidevox.com/#r2) But a separate controlled trial of single nightly GHRH(1-29) injections in healthy elderly men raised 24-hour GH and improved slow-wave sleep while **failing to change body weight, BMI, waist-hip ratio, lean body mass or fat mass**.[3](https://peptidevox.com/#r3) The takeaway, documented in FDA's own trial registry at [ClinicalTrials.gov](https://clinicaltrials.gov/) and the primary literature, is that sermorelin reliably raises the biomarker axis but functional body-composition benefits are inconsistent across the two small, ~30-year-old trials, with no modern large RCT.[14](https://peptidevox.com/#r14)

Proven vs hyped
Proven (Grade B): diagnostic provocative testing, improved height velocity in some GH-deficient children, and reliable IGF-1 elevation in older adults. Hyped (Grade C–D): robust fat loss, muscle gain, recovery and "reversing aging" — these exceed what the two small adult RCTs showed, and the human body-composition data are contradictory.[14](https://peptidevox.com/#r14)

## What doses appear in the literature?

Reported strictly as information, not a protocol. For the historical Geref Diagnostic provocative test, the regimen was a single 1 µg/kg intravenous bolus with timed GH sampling.[1](https://peptidevox.com/#r1)[7](https://peptidevox.com/#r7) For pediatric idiopathic GH deficiency, the historical therapeutic Geref dose was 30 µg/kg subcutaneously once nightly at bedtime, with injection-site rotation; bedtime timing exploits the natural nocturnal GH surge.[1](https://peptidevox.com/#r1)[7](https://peptidevox.com/#r7) Older-adult research used roughly 10 µg/kg subcutaneously nightly for up to sixteen weeks.[2](https://peptidevox.com/#r2) Historical lyophilized vials were reconstituted with sterile or bacteriostatic diluent and refrigerated; no current FDA-approved finished-product directions exist, and compounded-product instructions are pharmacy-specific.[18](https://peptidevox.com/#r18) Bedtime subcutaneous dosing and the short half-life are designed to mimic physiologic nocturnal GH pulses rather than sustain continuous stimulation.[5](https://peptidevox.com/#r5)

## How safe is sermorelin?

Sermorelin is generally well tolerated. The most common treatment-related event is a local injection-site reaction (pain, swelling, redness), occurring in about one patient in six; of 350 patients exposed in clinical trials, only three discontinued for injection reactions.[7](https://peptidevox.com/#r7) Other treatment-related events each occurred at under one percent: headache, flushing, dysphagia, dizziness, hyperactivity, somnolence and urticaria; the intravenous diagnostic route adds flushing, nausea, vomiting, dysgeusia, pallor and chest tightness.[7](https://peptidevox.com/#r7) A large proportion of patients developed anti-GRF (anti-GHRH) antibodies at least once; titers fluctuated, did not clearly correlate with growth response, and were not linked to a specific adverse-reaction profile.[7](https://peptidevox.com/#r7)

The dominant theoretical risk is mechanistic: because GH and IGF-1 are mitogenic and anabolic, there is concern about promoting growth of occult or active malignancy and possibly angiogenesis — so active cancer is treated as a contraindication for GH secretagogues despite the absence of direct sermorelin tumor data.[17](https://peptidevox.com/#r17)[5](https://peptidevox.com/#r5) The intact negative-feedback axis is the main reason sermorelin is thought less likely than recombinant GH to drive supraphysiologic IGF-1, which the older-adult RCT corroborated.[2](https://peptidevox.com/#r2) Hypersensitivity is an absolute contraindication; pregnancy and lactation are avoided for lack of data; and untreated hypothyroidism blunts the pituitary's GHRH response and should be corrected first.[7](https://peptidevox.com/#r7)[1](https://peptidevox.com/#r1)

## What is the FDA and WADA status in 2026?

Sermorelin acetate was FDA-approved twice: Geref Diagnostic (NDA 19-863) in 1990 for evaluating pituitary GH-secretory capacity, and Geref (NDA 20-443) on September 26, 1997 for treating idiopathic GH deficiency in children.[16](https://peptidevox.com/#r16)[6](https://peptidevox.com/#r6) The manufacturer voluntarily discontinued production in 2008 for commercial reasons — a small market and changing diagnostic practice — and marketing approval was withdrawn effective 2009.[4](https://peptidevox.com/#r4) Critically, in a March 4, 2013 Federal Register determination (Docket FDA-2012-P-1071), the FDA found that Geref injection was **not** withdrawn for reasons of safety or effectiveness.[4](https://peptidevox.com/#r4) There is no FDA-approved sermorelin finished product on the U.S. market today.

All sermorelin dispensed in 2026 is compounded under pharmacy law. On FDA's interim 503A bulk-substances list it sits in **Category 1** ("nominated, under evaluation, no significant safety concern"), where FDA's enforcement-discretion policy applies — unlike Category 2 substances such as BPC-157.[10](https://peptidevox.com/#r10)[11](https://peptidevox.com/#r11) This contrasts with the September 2024 removal of five other peptides (AOD-9604, CJC-1295, ipamorelin acetate, thymosin alpha-1, Selank) from Category 2, with continued advisory-committee review.[12](https://peptidevox.com/#r12) Off-label prescribing of compounded sermorelin by a licensed physician is generally lawful when medically justified, but it is not approved for weight loss, anti-aging or any adult metabolic indication, and marketing claiming otherwise is misleading.[11](https://peptidevox.com/#r11)

For athletes the picture is unambiguous. Sermorelin is prohibited at all times — in and out of competition — under WADA class S2.2.4, "Growth Hormone Releasing Hormones (GHRH) and their analogues," named alongside CJC-1293, CJC-1295 and tesamorelin.[8](https://peptidevox.com/#r8)[9](https://peptidevox.com/#r9) Detection is analytically challenging — after a single subcutaneous dose the intact peptide is not reliably recovered, though the sermorelin(3-29) metabolite has been identified at roughly thirty minutes.[15](https://peptidevox.com/#r15) Any WADA-tested athlete should treat it as banned.

**Bottom line.** Sermorelin pairs a real, if modest, human evidence base — diagnostic testing, pediatric GH deficiency, and reliable IGF-1 elevation — with a marketing narrative its data do not support. Graded B for its historical and biomarker-level uses; the anti-aging and performance positioning is preliminary at best. Regulatory facts here are current as of June 2026; compounding categories are fluid and should be re-verified before relying on this status.

---
Source: https://peptidevox.com/peptide-encyclopedia/sermorelin
Index: https://peptidevox.com/llms.txt · Full text: https://peptidevox.com/llms-full.txt